- Open Access
Hepatitis A virus (HAV) packaging size limit
© Konduru et al; licensee BioMed Central Ltd. 2009
- Received: 17 September 2009
- Accepted: 18 November 2009
- Published: 18 November 2009
Hepatitis A virus (HAV), an atypical Picornaviridae that causes acute hepatitis in humans, grows poorly in cell culture and in general does not cause cytopathic effect. Foreign sequences have been inserted into different parts of the HAV genome. However, the packaging size limit of HAV has not been determined. The purpose of the present study is to investigate the maximum size of additional sequences that the HAV genome can tolerate without loosing infectivity.
In vitro T7 polymerase transcripts of HAV constructs containing a 456-nt fragment coding for a blasticidin (Bsd) resistance gene, a 1,098-nt fragment coding for the same gene fused to GFP (GFP-Bsd), or a 1,032-nt fragment containing a hygromycin (Hyg) resistance gene cloned into the 2A-2B junction of the HAV genome were transfected into fetal Rhesus monkey kidney (FRhK4) cells. After antibiotic selection, cells transfected with the HAV construct containing the resistance gene for Bsd but not the GFP-Bsd or Hyg survived and formed colonies. To determine whether this size limitation was due to the position of the insertion, a 606 bp fragment coding for the Encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) sequence was cloned into the 5' nontranslated (NTR) region of HAV. The resulting HAV-IRES retained the EMCV IRES insertion for 1-2 passages. HAV constructs containing both the EMCV IRES at the 5' NTR and the Bsd-resistance gene at the 2A-2B junction could not be rescued in the presence of Bsd but, in the absence of antibiotic, the rescued viruses contained deletions in both inserted sequences.
HAV constructs containing insertions of approximately 500-600 nt but not 1,000 nt produced viable viruses, which indicated that the HAV particles can successfully package approximately 600 nt of additional sequences and maintain infectivity.
- Internal Ribosome Entry Site
- Foreign Sequence
- EMCV Internal Ribosome Entry Site
- FRhK4 Cell
- Fetal Rhesus Monkey Kidney
Hepatitis A virus (HAV), a member of the Picornaviridae family, causes acute hepatitis in humans. The 27-32 nm non-enveloped HAV icosahedral particles encapsidate a 7.5 kb single-stranded positive-sense RNA genome , which contains a long open reading frame (ORF) flanked by 5' and 3' end non-translated regions (NTR). The long 5' NTR of approximately 750 nucleotides (nt) has a complex structure and contains an internal ribosome entry site (IRES) required for viral translation. The 3' NTR is short and ends in a poly(A) tail . The HAV long ORF encodes a polyprotein of approximately 250 kDa that undergoes co- and post-translational processing into smaller structural (VP0, VP3, and VP1-2A) and non-structural (2B, 2C, 3A, 3B, 3C, and 3D) proteins [3, 4]. HAV 3C is a cysteine proteinase (3Cpro) responsible for most of the polyprotein cleavages and is the only protease coded in the HAV genome [5–9]. The 2A-2B junction is the primary cleavage site of the HAV polyprotein processed by 3Cpro [9, 10]. The VP0 undergoes structural cleavage, and an unknown host cellular protease cleaves the VP1-2A junction .
HAV is a hepatotropic virus transmitted through the fecal-oral route. Pathogenesis of HAV is poorly understood, and it is unclear whether the virus needs to replicate in extra-hepatic sites before reaching the liver. After binding to its cellular receptor HAVCR1 [12, 13], the HAV genome is delivered to the cytoplasm by an unknown mechanism. Once in the cytoplasm, the HAV genome is translated, transcribed, and encapsidated without in general causing cytopathic effect. The virus is eliminated by the immune system and does not establish chronic infection. Inactivated HAV vaccines are safe and effective, and are currently used in most of the world to prevent and treat HAV infection [1, 14, 15].
Considerable interest has been devoted to develop HAV as an expression vector for combination vaccines, expression of proteins in the liver, and basic research on this poorly understood human pathogen. We have previously shown that replication-competent HAV constructs containing inserts of 60-81 nt coding for malaria and FLAG-tag epitopes at the N-terminus of the HAV polyprotein were stable for at least 6 passages . An HAV recombinant containing 420-nt insertion at the 2A-2B junction was stable for up to five passages . HAV constructs carrying a seven amino acid human immunodeficiency virus gp41 epitope at the surface of the HAV particles elicited an immune response against gp41 in infected animals [17, 18]. Recently, we showed that a 456-nt fragment coding for a blasticidin (Bsd) resistant gene inserted at the 2A-2B junction of wild type HAV was stable for 9 passages , conferred Bsd resistance to infected cells, and was used to develop an antibiotic resistance titration assay to evaluate anti-HAV antibodies in preparations of human immunoglobulins . Although foreign sequences have been successfully inserted into different parts of the HAV, the packaging size limit of HAV has not been determined. To study the maximum size of foreign sequences that HAV could tolerate, we cloned exogenous sequences into the 2A-2B junction and/or N-terminus of the polyprotein. A 456-nt fragment coding for a Bsd resistance gene was engineered into the 2A-2B junction of HAV and maintained for 25 passages with or without antibiotic selection. A recombinant HAV containing the Encephalomyocarditis (EMCV) internal ribosome entry site (IRES) of 606 nt cloned at the 5'NTR between the HAV IRES and the initiation codon of the HAV polyprotein only maintained the insert for a few passages. However, recombinant HAV constucts containing approximately 1,000 nt at the 2A-2B junction or both the EMCV IRES at the 5'NTR and the Bsd resistance gene at the 2A-2B junction could not be rescued from transfected cells. Our results indicated that HAV has a restricted packaging size limit that can accommodate approximately 600 nt of additional sequences.
Insertions at the 2A-2B junction
Insertions at the 5' NTR
Insertions at both the 2A-2B junction and the 5'NTR
In this paper we studied the packaging size limit of HAV. The virus tolerated the insertion of approximately 500 nt at the 2A-2B junction and 600 nt at the 5'NTR. The insertion of 456-nt fragment coding for a Bsd resistance gene flanked by 3Cpro cleavage sites was remarkably stable for 25 passages even in the absence of antibiotic. However, HAV could not accommodate larger inserts in the same site, and viruses containing GFP-Bsd and Hyg selectable markers could not be rescued from transfected cells. It should be pointed out FRhk4 cells transfected with eukaryotic expression vectors containing the GFP-Bsd and Hyg resistance genes survived selection with Bsd and Hyg, respectively. Moreover, FRhK4 cells transfected with an eukaryotic expression vector containing the GFP-Bsd fusion protein fluoresced similarly to cells transfected with a construct containing only GFP (data not shown). Since HAVvec9-Bsd was very stable, it is unclear why we could not rescue an HAV construct containing GFP-Bsd. One simple explanation is that we exceeded the packaging size limit of HAV. However, cells transfected with pHAVvec9-GFP-Bsd in vitro transcripts did not survive selection with Bsd suggesting that packaging alone was not the only factor affecting infectivity. Therefore, we hypothesized that site-specific or sequence-specific constraints at the 2A-2B junction site prevented HAV replication. To test this hypothesis, we introduced a completely different sequence at another site of the HAV genome. To that effect, we cloned a 606-nt fragment coding for the EMCV IRES between the HAV IRES and the initiation codon of the HAV polyprotein. Because HAV containing the EMCV IRES was unstable and tended to delete the insert in a few passages, we limited our study to viruses produced at the initial passage. The failure to rescue virus from the construct containing the Bsd resistance gene at the 2A-2B junction and the EMCV IRES at the 5'NTR indicated that the maximum size of foreign sequences that can be incorporated into the HAV genome of a viable virus is approximately 600 nt. Our study showed that HAV can package genomes of approximately 8,100 nt composed of the full-length genome and an insertion of approximately 600 nt, which can accommodate an additional 200 amino acid protein into the HAV polyprotein. Although the size of the extra sequences is somehow limited, HAV could be used as an expression vector for the development of combination vaccines and delivery of genes to the liver.
In this study we showed that viable HAV can package full-length viral genomes containing insertions of approximately 600 nt.
Cells and viruses
Fetal rhesus monkey kidney (FRhK4) cells, a gift of S. Emerson, National Institutes of Health (NIH), were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The cell culture-adapted human HM-175 strain of HAV was derived from an infectious cDNA clone , termed HAV/7 , and grown in FRhK-4 cells. Nucleotide positions of the HAV genome are according to the published HM175 HAV cDNA sequence .
Bsd forward (SalI)
Bsd reverse (KpnI)
GFP forward (SalI)
Hyg forward (SalI)
Hyg reverse (KpnI)
EMVC IRES forward (XbaI)
EMVC IRES reverse (XbaI)
Insertions in the HAV 2A-2B junction or 5'NTR
Size (nt) *
pT7HAV contains the infectious cDNA cell culture-adapted HM-175 strain of HAV under the control of a T7 RNA polymerase promoter in pGEM1, and the in vitro transcripts were infectious in FRhK4 cells .
pHAVvec9 was derived from pT7HAV as described previously . pHAVvec9 contains a polylinker with unique SalI, SnaBI, and KpnI restriction sites.
pHAVvec9-Bsd contains Bsd gene cloned into the polylinker of the HAV cDNA in pHAVvec9 .
pHAVvec9-GFP-Bsd contains a GFP-Bsd fusion cloned into the HAV cDNA polylinker in pHAVvec9. The GFP-Bsd fusion was amplified by PCR from pTracer-CMV/Bsd (Invitrogen). To create unique SalI site in GFP-Bsd insert, a silent substitution mutation (from GTC GAC to GTA GAC) was introduced to eliminate SalI site in the GFP gene sequence using overlap PCR.
pHAVvec9-Hyg contains a Hyg resistance gene cloned into the HAV cDNA polylinker in pHAVvec9. The Hyg resistance gene was amplified by PCR from pCFB-EGSH (Stratagene).
pHAV-IRES contains the EMCV IRES (corresponding to 278-836 nt of the EMCV genome) cloned between the HAV IRES and the HAV polyprotein initiation codons in pT7HAV (Figure 3). To construct pHAV-IRES, a 606-nt cDNA fragment containing nt 278-836 of EMCV flanked at the 5' end by a XbaI site and at the 3'end by the two tandem initiation codons of the HAV polyprotein and an XbaI restriction site was amplified from pCITE-1 (Novagen), a plasmid containing the EMCV IRES. This amplified cDNA fragment was cut with XbaI and cloned into the unique XbaI site adjacent to the HAV initiation codons in pT7HAV.
pHAVvec9-Bsd-IRES was constructed by cloning the EMCV IRES from pHAV-IRES into pHAVvec9-Bsd. To do so, the 1,783-nt BspEI and BstEII fragment of pHAV-IRES containing the EMCV IRES was cloned into pHAVvec9-Bsd cut with BspEI and BstEII at nts 24 and 1194 of the HAV cDNA, respectively. The resulting construct contained both the EMCV IRES and the 5'NTR and the Bsd resistance gene at the 2A-2B junction of the HAV cDNA.
In vitro RNA synthesis and transfection
Synthesis of full-length HAV RNA transcripts was performed using T7 RNA polymerase . To do so, plasmids were linearized with HaeII, which cuts immediately downstream of the poly(A) of the HAV cDNA [16, 30]. Subconfluent FRhK4 cells in 25-cm2 flasks were transfected with in vitro synthesized RNA transcripts using DEAE-dextran as facilitator  or Lipofectamine 2000 (Invitrogen). After 30 min incubation at room temperature, fresh media was added to replace transfection solution and incubated at 35°C. Cells were split weekly into new flasks, and an aliquot was passed to 8-well chamber slides for immunofluorescence (IF) analysis. To prepare viral stocks, monolayers with approximately 80% of the cells expressing HAV antigens as assessed by IF analysis were subjected to three freeze-thaw cycles and clarified by low-speed centrifugation. Supernatants containing the virus stocks were stored at -70°C.
Immunofluorescence (IF) analysis
FRhK4 cells were grown in 8-well Permanox chamber slides (Nunc, Inc.) at 35°C in a CO2 incubator for 24-48 h. Cell culture media was aspirated and the cells were fixed with cold acetone for 30 min at -20°C. Fixed cell monolayers were air-dried, blocked with PBS-2% FBS at room temperature, and stained with a mix of anti-HAV neutralizing murine monoclonal antibodies K2-4F2 and K3-2F2  and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody (KPL, Inc). Stained slides were air-dried, coverslips were mounted with PermaFluor aqueous medium (Shandon Immunon, PA), and fluorescent micrographs were taken with a Zeiss Axioscope microscope at 400× magnification.
RT-PCR and nucleotide sequence analysis
RNA was extracted from HAV particles using QIAamp viral RNA mini kit (Qiagen). RT-PCR was carried out using the Superscript-II enzyme kit (Invitrogen). The cDNA was synthesized with primers corresponding to HAV nt position 3715-3738 or 1167-1194. PCR fragments were amplified using primers corresponding to HAV nts 2928-2951 and 3715-3738 or 484-507 and 1167-1194. Amplified DNA fragments were gel purified, and sequenced using the ABI Prism BigDye terminator cycle-sequencing ready reaction kit (Applied Biosystems) and with ABI Prism (model 3100) analyzer (Applied Biosystems).
We thank Susan Zullo for critical review of the manuscript. The work was supported by FDA intramural funding to GGK. This project was supported in part by the appointment of SMN to the Research Participation Program at the Center for Biologics Evaluation and Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. All authors read and approved the final manuscript.
- Hollinger FB, Emerson SU: Hepatitis A Virus. In Fields Virology Fifth edition. Edited by: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE. 2007, 912-947.Google Scholar
- Glass MJ, Jia XY, Summers DF: Identification of the hepatitis A virus internal ribosome entry site: in vivo and in vitro analysis of bicistronic RNAs containing the HAV 5' noncoding region. Virology 1993, 193: 842-852. 10.1006/viro.1993.1193View ArticlePubMedGoogle Scholar
- Harmon SA, Updike W, Jia XY, Summers DF, Ehrenfeld E: Polyprotein processing in cis and in trans by hepatitis A virus 3C protease cloned and expressed in Escherichia coli. J Virol 1992, 66: 5242-5247.PubMed CentralPubMedGoogle Scholar
- Jia XY, Summers DF, Ehrenfeld E: Primary cleavage of the HAV capsid protein precursor in the middle of the proposed 2A coding region. Virology 1993, 193: 515-519. 10.1006/viro.1993.1157View ArticlePubMedGoogle Scholar
- Bergmann EM, Mosimann SC, Chernaia MM, Malcolm BA, James MN: The refined crystal structure of the 3C gene product from hepatitis A virus: specific proteinase activity and RNA recognition. J Virol 1997, 71: 2436-2448.PubMed CentralPubMedGoogle Scholar
- Schultheiss T, Kusov YY, Gauss-Muller V: Proteinase 3C of hepatitis A virus (HAV) cleaves the HAV polyprotein P2-P3 at all sites including VP1/2A and 2A/2B. Virology 1994, 198: 275-281. 10.1006/viro.1994.1030View ArticlePubMedGoogle Scholar
- Schultheiss T, Sommergruber W, Kusov Y, Gauss-Muller V: Cleavage specificity of purified recombinant hepatitis A virus 3C proteinase on natural substrates. J Virol 1995, 69: 1727-1733.PubMed CentralPubMedGoogle Scholar
- Martin A, Benichou D, Chao SF, Cohen LM, Lemon SM: Maturation of the hepatitis A virus capsid protein VP1 is not dependent on processing by the 3Cpro proteinase. J Virol 1999, 73: 6220-6227.PubMed CentralPubMedGoogle Scholar
- Martin A, Escriou N, Chao SF, Girard M, Lemon SM, Wychowski C: Identification and site-directed mutagenesis of the primary (2A/2B) cleavage site of the hepatitis A virus polyprotein: functional impact on the infectivity of HAV RNA transcripts. Virology 1995, 213: 213-222. 10.1006/viro.1995.1561View ArticlePubMedGoogle Scholar
- Beard MR, Cohen L, Lemon SM, Martin A: Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction. J Virol 2001, 75: 1414-1426. 10.1128/JVI.75.3.1414-1426.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Graff J, Richards OC, Swiderek KM, Davis MT, Rusnak F, Harmon SA, Jia XY, Summers DF, Ehrenfeld E: Hepatitis A virus capsid protein VP1 has a heterogeneous C terminus. J Virol 1999, 73: 6015-6023.PubMed CentralPubMedGoogle Scholar
- Kaplan G, Totsuka A, Thompson P, Akatsuka T, Moritsugu Y, Feinstone SM: Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. Embo J 1996, 15: 4282-4296.PubMed CentralPubMedGoogle Scholar
- Feigelstock D, Thompson P, Mattoo P, Zhang Y, Kaplan GG: The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor. J Virol 1998, 72: 6621-6628.PubMed CentralPubMedGoogle Scholar
- Martin A, Lemon SM: Hepatitis A virus: from discovery to vaccines. Hepatology 2006, 43: S164-172. 10.1002/hep.21052View ArticlePubMedGoogle Scholar
- Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, Favorov MO, Margolis HS, Bell BP: Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007, 357: 1685-1694. 10.1056/NEJMoa070546View ArticlePubMedGoogle Scholar
- Zhang Y, Kaplan GG: Characterization of replication-competent hepatitis A virus constructs containing insertions at the N terminus of the polyprotein. J Virol 1998, 72: 349-357.PubMed CentralPubMedGoogle Scholar
- Beneduce F, Kusov Y, Klinger M, Gauss-Muller V, Morace G: Chimeric hepatitis A virus particles presenting a foreign epitope (HIV gp41) at their surface. Antiviral Res 2002, 55: 369-377. 10.1016/S0166-3542(02)00073-6View ArticlePubMedGoogle Scholar
- Kusov YY, Zamjatina NA, Poleschuk VF, Michailov MI, Morace G, Eberle J, Gauss-Muller V: Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5. Antiviral Res 2007, 73: 101-111. 10.1016/j.antiviral.2006.08.003View ArticlePubMedGoogle Scholar
- Konduru K, Kaplan GG: Stable growth of wild-type hepatitis A virus in cell culture. J Virol 2006, 80: 1352-1360. 10.1128/JVI.80.3.1352-1360.2006PubMed CentralView ArticlePubMedGoogle Scholar
- Konduru K, Virata-Theimer ML, Yu MY, Kaplan GG: A simple and rapid Hepatitis A Virus (HAV) titration assay based on antibiotic resistance of infected cells: evaluation of the HAV neutralization potency of human immune globulin preparations. Virol J 2008, 5: 155. 10.1186/1743-422X-5-155PubMed CentralView ArticlePubMedGoogle Scholar
- Whetter LE, Day SP, Elroy-Stein O, Brown EA, Lemon SM: Low efficiency of the 5' nontranslated region of hepatitis A virus RNA in directing cap-independent translation in permissive monkey kidney cells. J Virol 1994, 68: 5253-5263.PubMed CentralPubMedGoogle Scholar
- Borman AM, Bailly JL, Girard M, Kean KM: Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. Nucleic Acids Res 1995, 23: 3656-3663. 10.1093/nar/23.18.3656PubMed CentralView ArticlePubMedGoogle Scholar
- Dove B, Cavanagh D, Britton P: Presence of an encephalomyocarditis virus internal ribosome entry site sequence in avian infectious bronchitis virus defective RNAs abolishes rescue by helper virus. J Virol 2004, 78: 2711-2721. 10.1128/JVI.78.6.2711-2721.2004PubMed CentralView ArticlePubMedGoogle Scholar
- McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA: A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 2003, 38: 503-508. 10.1053/jhep.2003.50330View ArticlePubMedGoogle Scholar
- Osorio JE, Powell TD, Frank RS, Moss K, Haanes EJ, Smith SR, Rocke TE, Stinchcomb DT: Recombinant raccoon pox vaccine protects mice against lethal plague. Vaccine 2003, 21: 1232-1238. 10.1016/S0264-410X(02)00557-1View ArticlePubMedGoogle Scholar
- Borman AM, Le Mercier P, Girard M, Kean KM: Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res 1997, 25: 925-932. 10.1093/nar/25.5.925PubMed CentralView ArticlePubMedGoogle Scholar
- Blight KJ, Kolykhalov AA, Rice CM: Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290: 1972-1974. 10.1126/science.290.5498.1972View ArticlePubMedGoogle Scholar
- Ikeda M, Yi M, Li K, Lemon SM: Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002, 76: 2997-3006. 10.1128/JVI.76.6.2997-3006.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285: 110-113. 10.1126/science.285.5424.110View ArticlePubMedGoogle Scholar
- Cohen JI, Rosenblum B, Ticehurst JR, Daemer RJ, Feinstone SM, Purcell RH: Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci USA 1987, 84: 2497-2501. 10.1073/pnas.84.8.2497PubMed CentralView ArticlePubMedGoogle Scholar
- Cohen JI, Rosenblum B, Feinstone SM, Ticehurst J, Purcell RH: Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA. J Virol 1989, 63: 5364-5370.PubMed CentralPubMedGoogle Scholar
- Cohen JI, Ticehurst JR, Feinstone SM, Rosenblum B, Purcell RH: Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J Virol 1987, 61: 3035-3039.PubMed CentralPubMedGoogle Scholar
- Maniatis T, Fritsch EF, Sambrook J: Molecular cloning: a laboratory manual. 2nd edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; 1989.Google Scholar
- Pagano JS, Vaheri A: Enhancement of infectivity of poliovirus RNA with diethylaminoethyl-dextran (DEAE-D). Arch Gesamte Virusforsch 1965, 17: 456-464. 10.1007/BF01241201View ArticlePubMedGoogle Scholar
- Dotzauer A, Feinstone SM, Kaplan G: Susceptibility of nonprimate cell lines to hepatitis A virus infection. J Virol 1994, 68: 6064-6068.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.